MELD 3.0 Score EXCLUDING Serum Albumin

 

Input
 

Sex	Female (1.4)
	Male (0)
Total Bilirubin		mcmol/L mg% mg/dL
Serum Creatinine		mcmol/L mg/dL mmol/L
INR		- ratio
Serum Sodium		mEq/L mmol/L

 
Results
 
Important: Inputs must be complete to perform calculation.

 

MELD 3.0 Score Without Albumin		# count index logit none number points score
90-Day Survival Estimation		% fraction percent rate ratio
60-Day Survival Estimation		% fraction percent rate ratio
30-Day Survival Estimation		% fraction percent rate ratio

 

 

 

Notes

• The MELD 3.0 Score accounts for intrinsic differences in Serum Creatinine between females and males.
• In previous iterations of MELD, these differences might bias the calculation and interpretation by resulting in lower MELD scores in females than males with otherwise identical risk factors.
• If a patient has not received intravenous albumin infusions, consider using the MELD 3.0 Score Including Serum Albumin calculator.
• MELD: Model for End-Stage Liver Disease.

 
Equations used
 

MELD 3.0 Score Without Albuminumin = Math.round(Sex + (4.85 * ln(Total Bilirubin)) + (0.88 * (137 - Serum Sodium)) - (0.25 * (137 - Serum Sodium) * ln(Total Bilirubin)) + (9.66 * ln(INR)) + (10.47 * ln(Serum Creatinine)) + 6)

90-Day Survival Estimation = 100 * 0.946e(0.17698*MELD 3.0 Score Without Albuminumin-3.56)

60-Day Survival Estimation = 100 * 0.963e(0.17698*MELD 3.0 Score Without Albuminumin-3.56)

30-Day Survival Estimation = 100 * 0.981e(0.17698*MELD 3.0 Score Without Albuminumin-3.56)

 

 

Calculation Details and Variables

• Total Bilirubin, Serum Creatinine, and INR values are set to 1 if measured values are less than 1.
• Serum Creatinine is set to 3 mg/dL for all measured values >3 mg/dL.
• Serum Sodium is similarly bound 125-137 mEq/L.
• Serum Albumin is similarly bound 1.5-3.5 g/dL.

 
Equation parameters such as Sex, have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g. (1.4), represent the values that will be used.
 

 

References

1. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021; 161:1887.